Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China's Leading CRO WuXi Looks To Utilize Manufacturing Capacity With Telaprevir

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Leading Chinese contract research organization WuXi PharmaTech Co., Ltd. recorded a strong quarter with revenue up 16% over the same period last year to $93.6 million, and the company is readying itself for big increases in its manufacturing business thanks to large-scale contracts generated from discovery deals

You may also be interested in...

After Another Strong Quarter, WuXi Aims To Become Backbone Of China’s Life Science Industry: China Earnings Roundup (Part 1)

Despite a macroeconomic slowdown, China’s leading CRO reported another strong quarter due to increasing demand for R&D services from both international and domestic companies.

WuXi PharmaTech Attempts To Tame The Tiger Of Labor Inflation As It Feels The Pinch In 2012: China Earnings Roundup (Part 2)

WuXi invests heavily to offer differentiated services with premium prices to counter growing labor costs in China; moves more facilities inland for cheaper labor.

Merck Looks To Leverage "Next 10" For Growth: Emerging Markets Earnings Roundup (Part 4)

Emerging markets remained a key focus of Big Pharma during first quarter earnings calls. Merck & Co., which aims to see one-fourth of its revenue come from emerging markets by 2013, focused investment in best growth drivers and sales efficiency to bolster key products. Merck's emerging markets strategy will focus on maximizing its own brands, leveraging partnerships with low-cost makers and looking for "inter-brand" opportunities.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts